secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2026-06-29T12:00:50+00:00
Accession:  0001404644-26-000046
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene reports positive Phase 1/2 data for NGN-401 in Rett syndrome; 47 milestones gained across 10 patients
--------------------------------------------------------------------------------

- 47 developmental milestones gained across 10 participants (avg 4.7); 100% improved CGI-I and gained ≥1 milestone.
- Durable effect through 30 months with no plateau or milestone loss; median time to first improvement 2 months.
- NGN-401 generally well-tolerated; no new treatment-related SAEs since Oct 2025; all AEs mild or moderate.
- Dosing complete in Embolden registrational trial; no treatment-related SAEs or DLTs; topline data expected 2H 2027.
- Improvements across RSGMS and RSHFS scales (p<0.001); 7/10 gained ≥2 milestones across ≥2 Rett domains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000046/0001404644-26-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000046/ngne-20260629.htm
  HTML page:      https://secwatch.observer/filing/0001404644-26-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer